Total Payments
$49,170
2024 Payments
$5,522
Companies
45
Transactions
347
Medicare Patients
3,156
Medicare Billing
$340,403
Payment Breakdown by Category
Other$23,200 (47.2%)
Consulting$13,914 (28.3%)
Food & Beverage$6,087 (12.4%)
Travel$5,587 (11.4%)
Education$382.12 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,200 | 8 | 47.2% |
| Consulting Fee | $13,914 | 9 | 28.3% |
| Food and Beverage | $6,087 | 308 | 12.4% |
| Travel and Lodging | $5,587 | 13 | 11.4% |
| Education | $382.12 | 9 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26,641 | 28 | $0 (2022) |
| Gilead Sciences, Inc. | $4,945 | 14 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $4,474 | 28 | $0 (2024) |
| PFIZER INC. | $3,431 | 34 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,930 | 24 | $0 (2024) |
| ABBVIE INC. | $2,538 | 10 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $517.22 | 34 | $0 (2024) |
| Amgen Inc. | $390.01 | 14 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $382.60 | 26 | $0 (2021) |
| Incyte Corporation | $360.08 | 3 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,522 | 45 | Gilead Sciences, Inc. ($4,912) |
| 2023 | $2,540 | 12 | ABBVIE INC. ($2,413) |
| 2022 | $1,242 | 20 | Boehringer Ingelheim Pharmaceuticals, Inc. ($800.00) |
| 2021 | $790.64 | 16 | Boehringer Ingelheim Pharmaceuticals, Inc. ($409.42) |
| 2020 | $254.28 | 11 | Rigel Pharmaceuticals, Inc. ($65.40) |
| 2019 | $10,259 | 71 | Boehringer Ingelheim Pharmaceuticals, Inc. ($8,985) |
| 2018 | $10,022 | 61 | Boehringer Ingelheim Pharmaceuticals, Inc. ($9,262) |
| 2017 | $18,541 | 111 | Boehringer Ingelheim Pharmaceuticals, Inc. ($7,185) |
All Payment Transactions
347 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.72 | General |
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $24.58 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $13.90 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.67 | General |
| Category: Hematology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $28.33 | General |
| Category: ONCOLOGY | ||||||
| 10/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.97 | General |
| 10/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.41 | General |
| Category: Hematology | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Consulting Fee | Cash or cash equivalent | $3,660.00 | General |
| Category: ONC | ||||||
| 10/17/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $22.00 | General |
| Category: ONC | ||||||
| 10/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $59.96 | General |
| Category: ONC | ||||||
| 10/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $56.65 | General |
| Category: ONC | ||||||
| 10/12/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $56.65 | General |
| Category: ONC | ||||||
| 10/11/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $668.04 | General |
| Category: ONC | ||||||
| 10/11/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: ONC | ||||||
| 10/11/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $13.96 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $15.29 | General |
| Category: Hematology | ||||||
| 09/24/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $14.77 | General |
| Category: Hematology | ||||||
| 09/17/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $13.20 | General |
| Category: Oncology | ||||||
| 09/10/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $28.60 | General |
| Category: Oncology | ||||||
| 08/28/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $16.38 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 08/06/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: Oncology | ||||||
| 07/30/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.63 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 791 | 1,528 | $304,968 | $101,341 |
| 2022 | 10 | 729 | 1,352 | $204,312 | $81,641 |
| 2021 | 13 | 798 | 1,400 | $164,468 | $79,667 |
| 2020 | 13 | 838 | 1,646 | $190,202 | $77,754 |
Total Patients
3,156
Total Services
5,926
Medicare Billing
$340,403
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 181 | 701 | $142,779 | $48,607 | 34.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 298 | 389 | $51,587 | $16,273 | 31.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 78 | 148 | $42,620 | $15,764 | 37.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 46 | 46 | $20,129 | $5,980 | 29.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 64 | 64 | $21,533 | $5,829 | 27.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 62 | $9,821 | $3,655 | 37.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 37 | $8,392 | $3,138 | 37.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 13 | $3,775 | $1,291 | 34.2% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 13 | 13 | $2,496 | $322.79 | 12.9% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 13 | 17 | $856.80 | $175.95 | 20.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 16 | 19 | $273.60 | $159.60 | 58.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 14 | 19 | $706.80 | $144.59 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 163 | 580 | $95,352 | $40,203 | 42.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 278 | 384 | $40,550 | $16,412 | 40.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 56 | 85 | $19,788 | $8,820 | 44.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 52 | 52 | $14,040 | $4,786 | 34.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 29 | 29 | $10,196 | $3,498 | 34.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 48 | $6,854 | $2,703 | 39.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 27 | 50 | $7,920 | $2,463 | 31.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 24 | 28 | $6,350 | $2,080 | 32.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 23 | 30 | $1,512 | $313.80 | 20.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 24 | 35 | $1,302 | $269.23 | 20.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 20 | 31 | $446.40 | $92.13 | 20.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 122 | 347 | $47,537 | $24,906 | 52.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 324 | 517 | $45,496 | $23,054 | 50.7% |
About Dr. Raymond Lobins, DO
Dr. Raymond Lobins, DO is a Hematology & Oncology healthcare provider based in Springfield, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356391064.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raymond Lobins, DO has received a total of $49,170 in payments from pharmaceutical and medical device companies, with $5,522 received in 2024. These payments were reported across 347 transactions from 45 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($23,200).
As a Medicare-enrolled provider, Lobins has provided services to 3,156 Medicare beneficiaries, totaling 5,926 services with total Medicare billing of $340,403. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Springfield, MO
- Active Since 05/11/2006
- Last Updated 08/03/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1356391064
Products in Payments
- GILOTRIF (Drug) $22,681
- ELIQUIS (Drug) $7,201
- Trodelvy (Drug) $4,848
- IMFINZI (Drug) $2,685
- VENCLEXTA (Drug) $2,405
- OPDIVO (Biological) $274.47
- KEYTRUDA (Biological) $247.78
- REBLOZYL (Biological) $178.59
- KISQALI (Drug) $174.37
- FOUNDATIONONE (Device) $167.88
- Avastin (Biological) $138.51
- MEKINIST (Drug) $137.96
- Neulasta (Biological) $132.26
- Pomalyst (Drug) $130.83
- Venclexta (Drug) $125.03
- BRUKINSA (Drug) $122.29
- IBRANCE (Drug) $101.63
- Oncology (Device) $101.63
- AFINITOR (Drug) $98.14
- Enhertu (Drug) $92.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Springfield
Dr. Joshua Strauss, M.d, M.D
Hematology & Oncology — Payments: $546,737
Hematology & Oncology $546,737
Dr. Preet Singh, Md, MD
Hematology & Oncology — Payments: $460,137
Hematology & Oncology $460,137
Dr. Ashish Shah, D.o, D.O
Hematology & Oncology — Payments: $323,857
Hematology & Oncology $323,857
Syed Ali, Md, MD
Hematology & Oncology — Payments: $237,324
Hematology & Oncology $237,324
Dr. Maithili Rao, M.d, M.D
Hematology & Oncology — Payments: $102,596
Hematology & Oncology $102,596
Ashish Khot, Md, MD
Hematology & Oncology — Payments: $79,812
Hematology & Oncology $79,812